Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Cited by (1,110)

Items 401–500 of 1,110

1. Interaction of smoking, hyperhomocysteinemia, and metabolic syndrome with carotid atherosclerosis: A cross-sectional study in 972 non-diabetic patients
   Mohamed Reza Azarpazhooh, Mohammad Sobhan Sheikh Andalibi, Daniel G. Hackam, John David Spence · 2020 · Nutrition
2. Egészségügyi szakmai irányelv – A diabetes mellitus kórismézéséről, a cukorbetegek antihyperglykaemiás kezeléséről és gondozásáról felnőttkorban
   Jermendy György, Zsolt Gaál, László Gerő, Tibor Hídvégi, Péter Kempler, Gábor Winkler, István Wittmann · 2017 · Diabetologia Hungarica
3. Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
   Ji Hye Heo, Kyung Ah Han, Jun Hwa Hong, Hyun-Ae Seo, Eun‐Gyoung Hong, Jae Myung Yu, Hye Seung Jung, Bong Soo · 2024 · Diabetes & Metabolism Journal
4. Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes
   Roya Ghafoury, Mojtaba Malek, Faramarz Ismail‐Beigi, Mohammad E. Khamseh · 2025 · Diabetes Therapy
5. Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems
   Aayush Kaushal, Aanchal Musafir, Gourav Sharma, Shital Rani, Rajat Kumar Singh, Akhilesh Kumar, Sanjay Kumar Bhadada, Ravi Pratap Barnwal, Gurpal Singh · 2025 · Pharmaceutics
6. What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?
   Deepu David, C. E. Eapen · 2020 · Journal of Clinical and Experimental Hepatology
7. Diabetes, Lipids, and CV Risk
   Jan Škrha · 2021 · Current Atherosclerosis Reports
8. The risk of carotid plaque instability in patients with metabolic syndrome is higher in women with hypertriglyceridemia
   Francesca Servadei, Lucia Anemona, Marina Cardellini, Manuel Scimeca, Manuela Montanaro, Valentina Rovella, Francesca Di Daniele, Erica Giacobbi, Iacopo Maria Legramante, Annalisa Noce et al. · 2021 · Cardiovascular Diabetology
9. Omega-3 fatty acid-rich fish oil supplementation prevents rosiglitazone-induced osteopenia in aging C57BL/6 mice and in vitro studies
   Chiara Cugno, Dhanya Kizhakayil, Rita Calzone, Shaikh Mizanoor Rahman, Ganesh V. Halade, Md Mamunur Rahman · 2021 · Scientific Reports
10. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?
    Carolina María Perdomo, Nuria Garcı́a-Fernández, Javier Escalada · 2021 · Journal of Clinical Medicine
11. Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review
    Ibrahimkhalil M Sheikh, Omar A Hassan, Siad Mohammed Adam, Abdirazak I Ali, Oboseh J Ogedegbe, Godfrey Tabowei, Ahmed Barbarawi, Feisal M Yussuf, Mohammed A Nor · 2023 · Cureus
12. Comparative effects of glucose-lowering agents on endothelial function and arterial stiffness in patients with type 2 diabetes: A network meta-analysis
    Hayeon Kim, Cheol Ung Choi, Kiyon Rhew, Jiwon Park, Yejee Lim, Myeong Gyu Kim, Kyungim Kim · 2024 · Atherosclerosis
13. Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide ‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database
    Matthew Anson, Alex E. Henney, Sizheng Steven Zhao, Gema Hernández, Gregory Y.H. Lip, Daniel James Cuthbertson, Katarzyna Nabrdalik, Uazman Alam · 2024 · Diabetes Obesity and Metabolism
14. Cardiovascular effects of anti-diabetes drugs
    Lisa M. Younk, Elizabeth Mary Lamos, Stephen N. Davis · 2016 · Expert Opinion on Drug Safety
15. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes
    Simona Cernea, Avivit Cahn, Itamar Raz · 2017 · Expert Review of Clinical Pharmacology
16. Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure
    Frederik Hendrik Verbrugge · 2017 · Current Heart Failure Reports
17. PPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice
    Tobias Gutting, Christian A. Weber, Philip Weidner, Frank Herweck, Sarah Henn, Teresa Friedrich, Shuiping Yin, Julia G. Kzhyshkowska, Timo Gaiser, Klaus‐Peter Janssen et al. · 2018 · OncoImmunology
18. Towards more specific treatment for diabetic dyslipidemia
    Valentina Rodriguez, Jonathan D. Newman, Arthur Z. Schwartzbard · 2018 · Current Opinion in Lipidology
19. Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients
    Cristina-Mihaela Lăcătușu, Elena-Daniela Grigorescu, Cristian Stătescu, Radu Andy Sascău, Alina Onofriescu, Bogdan Mircea Mihai · 2019 · Medicina
20. The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider
    Lavanya Cherukuri, Michael Seth Smith, John A. Tayek · 2018
21. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes
    Michael E. Nassif, Mikhail Kosiborod · 2019 · The American Journal of Cardiology
22. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update – The User’s Guide
    Peter Alexander Senior, Robyn L. Houlden, James Kim, Dylan MacKay, Seema Nagpal, Doreen M. Rabi, Diana Sherifali, HARPREET SINGH BAJAJ · 2020 · Canadian Journal of Diabetes
23. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
    Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO) · 2021 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
24. Homeostasis model assessment of insulin resistance and outcome of ischemic stroke in non-diabetic patients - a prospective observational study
    Daniel Åberg, N. David Åberg, Katarina Jood, Lukas Holmegaard, Petra Redfors, Christian Blomstrand, Jörgen Isgaard, Christina Jern, Johan Svensson · 2019 · BMC Neurology
25. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis
    Fu‐Shun Yen, James Cheng‐Chung Wei, Lu‐Ting Chiu, Chih‐Cheng Hsu, Ming‐Chih Hou, Chii‐Min Hwu · 2020 · Liver International
26. Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database
    Shih‐Chang Lo, Edy Kornelius, Pei‐Lun Liao, Jing‐Yang Huang, Yi‐Sun Yang, Chien‐Ning Huang · 2023 · Diabetes Research and Clinical Practice
27. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus
    Stanley S. Schwartz, Farhad Zangeneh · 2016 · Postgraduate Medicine
28. Liraglutide effects on beta‐cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes
    Christian Anholm, Preman Kumarathurai, Lene Rørholm Pedersen, Olav Wendelboe Nielsen, Ole Peter Kristiansen, Mogens Fenger, Sten Madsbad, Ahmad Sajadieh, Steen B. Haugaard · 2017 · Diabetes Obesity and Metabolism
29. Practical strategies for improving outcomes in T2DM : T he potential role of pioglitazone and DPP4 inhibitors
    Stefano Del Prato, ROBERT J. CHILTON · 2017 · Diabetes Obesity and Metabolism
30. Design and baseline characteristics of the AMPLITUDE‐O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist
    Hertzel C. Gerstein, Kelley R. Branch, Laura Heenan, Stefano Del Prato, Nardev Singh Khurmi, Carolyn S.P. Lam, Richard E. Pratley, Julio Rosenstock, Naveed A. Sattar · 2020 · Diabetes Obesity and Metabolism
31. Natural flavonoids from herbs and nutraceuticals as ferroptosis inhibitors in central nervous system diseases: current preclinical evidence and future perspectives
    Qiuhe Li, Xiaohang Yang, Tiegang Li · 2025 · Frontiers in Pharmacology
32. Bias and Loss to Follow‐Up in Cardiovascular Randomized Trials: A Systematic Review
    Lucas Chun Wah Fong, Thomas Joseph Ford, Bruno R. da Costa, Peter Jüni, Colin Berry · 2020 · Journal of the American Heart Association
33. Caring for Patients With Diabetes in Stroke Neurology
    Walter N. Kernan, Rachel Forman, Silvio E. Inzucchi · 2022 · Stroke
34. Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
    Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim · 2023 · Cardiovascular Diabetology
35. Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
    Almudena Castro Conde, Domingo Marzal Martín, Raquel Campuzano Ruíz, María Rosa Fernández Olmo, Carlos Morillas Ariño, Juan José Gómez‐Doblas, José Luis Górriz, Pilar Mazón‐Ramos, Xavier García–Moll, María José Soler et al. · 2023 · Journal of Clinical Medicine
36. SGLT2 Inhibitors—Sweet Success for Diabetic Kidney Disease?
    Ian H. de Boer, Steven E. Kahn · 2016 · Journal of the American Society of Nephrology
37. Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study
    Helen Strongman, Pasi A. Korhonen, Rachael Williams, Shahram Bahmanyar, Fabian J. Hoti, Solomon Christopher, Maila Majak, Leanne Kool-Houweling, Marie Linder, Paul Dolin et al. · 2017 · BMJ Open Diabetes Research & Care
38. Heart Failure
    Anders Jorsal, Henrik Wiggers, John J.V. McMurray · 2017 · Endocrinology and Metabolism Clinics of North America
39. Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction
    Masanori Wakisaka, Masahiro Kamouchi, Takanari Kitazono · 2019 · International Journal of Molecular Sciences
40. The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
    Linda Wu, Jenny Elizabeth Gunton · 2019 · International Journal of Molecular Sciences
41. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021)
    Irina Evgen'evna Chazova, Marina Vladimirovna Shestakova, Yu. V. Zhernakova, Nataliya V. Blinova, Т. Н. Маркова, Natalya Valentinovna Mazurina, Ежов Марат Владиславович, Sergey N. Tereshchenko, И. В. Жиров, Andrey L. Komarov et al. · 2021 · Eurasian heart journal
42. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack
    Jia Liu, Lu‐Ning Wang · 2019 · Cochrane Database of Systematic Reviews
43. Pancreatic β-Cell Function and Prognosis of Nondiabetic Patients With Ischemic Stroke
    Yuesong Pan, Weiqi Chen, Jing Jing et al. · 2017 · Stroke
44. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
    Alexander Niessner, Juan Luis Tamargo, Lorenz Koller, Christoph H. Saely, Thomas Andersen Schmidt, Gianluigi Savarese, Sven Waßmann, Giuseppe M.C. Rosano, Claudio Ceconi, Christian Tobias Torp-Pedersen et al. · 2017 · European Heart Journal
45. Insulin resistance is an independent risk factor for early neurological deterioration in non-diabetic patients with acute ischemic stroke
    Donghua Mi, Yilong Wang, Yongjun Wang, Liping Liu · 2020 · Neurological Sciences
46. A systematic review of subgroup analyses in randomised clinical trials in cardiovascular disease
    Korbinian Brand, Alexander Hapfelmeier, Bernhard Haller · 2021 · Clinical Trials
47. The effect of thiazolidinediones on body fat redistribution in adults: A systematic review and meta‐analysis of randomized controlled trials
    Fang Zhang, Xiaohui Pan, Xinyue Zhang, Nanwei Tong · 2023 · Obesity Reviews
48. Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
    John E. Anderson, Eugene E. Wright, Charles F. Shaefer · 2016 · Diabetes Therapy
49. Free Fatty Acid Is Associated with Thrombogenicity in Cardioembolic Stroke
    Woo‐Keun Seo, Jin‐Man Jung, Ji Hyun Kim, Seong‐Beom Koh, Oh Young Bang, Kyungmi Oh · 2017 · Cerebrovascular Diseases
50. Current aspects of TIA management
    Benjamin G. Clissold, Thanh G. Phan, John V Ly, Shaloo Singhal, Velandai K. Srikanth, Henry Ma · 2020 · Journal of Clinical Neuroscience
51. Evaluation of Browning Agents on the White Adipogenesis of Bone Marrow Mesenchymal Stromal Cells: A Contribution to Fighting Obesity
    Girolamo Di Maio, Nicola Alessio, İbrahim Halil Demirsoy, Gianfranco Peluso, Silverio Perrotta, Marcellino Monda, Giovanni Di Bernardo · 2021 · Cells
52. Stroke Prevention: Little-Known and Neglected Aspects
    Mahmoud Reza Azarpazhooh, Chrysi Bogiatzi, John David Spence · 2021 · Cerebrovascular Diseases
53. Update on Management of Type 2 Diabetes for Cardiologists
    Mohammed Qureshi, Emily Gammoh, Jawairia Shakil, Richard J. Robbins · 2018 · Methodist DeBakey Cardiovascular Journal
54. Diabetes and cardiovascular disease in older adults
    Anika Bilal, Richard E. Pratley · 2024 · Annals of the New York Academy of Sciences
55. Association between Triglyceride-Glucose indices and ischemic stroke risk across different glucose metabolism statuses
    Keyu Bian, Chao Hou, Huafeng Jin, Xiaoli Feng, Min Peng, Xingqi Zhao, Xiaomei Yuan, Wenguang Sun, Haixing Feng, Gelin Xu · 2025 · Diabetes Research and Clinical Practice
56. Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice
    Catherine M. Davis, Wenri H. Zhang, Elyse M. Allen, Thierno Madjou Bah, Robert E. Shangraw, Nabil J. Alkayed · 2021 · International Journal of Molecular Sciences
57. The effect of hsCRP on TyG index-associated cardiovascular risk in patients with acute coronary syndrome undergoing PCI
    Xiaoteng Ma, Huijun Chu, Yan Sun, Yujing Cheng, Dai Zhang, Yujie Zhou, Xiaoli Liu, Zhijian Wang · 2024 · Scientific Reports
58. Interventions in type 2 diabetes mellitus and cardiovascular mortality–An overview of clinical trials
    Benjamin Burggraaf, Manuel Castro Cabezas · 2017 · European Journal of Internal Medicine
59. Reversing the curse on PPARγ
    Mitchell A. Lazar · 2018 · Journal of Clinical Investigation
60. Accurate diagnosis of diabetes mellitus and new paradigms of classification
    Sudesna Chatterjee, Melanie Jane Davies · 2018 · Nature Reviews Endocrinology
61. A performance guide for major risk factors control in patients with atherosclerotic cardiovascular disease in Taiwan
    Yi‐Heng Li, Jaw‐Wen Chen, Tsung‐Hsien Lin, Yu-Chen Wang, Chau‐Chung Wu, Hung‐I Yeh, Chin‐Chou Huang, Kuan‐Cheng Chang, Cho‐Kai Wu, Po‐Wei Chen et al. · 2019 · Journal of the Formosan Medical Association
62. [Early gastric cancer: epidemiology, diagnostic and management].
    Thibaud Koessler, A. Roth, Wulfran Cacheux · 2014 · PubMed
63. Pathobiology of Prediabetes: Understanding and Interrupting Progressive Dysglycemia and Associated Complications
    Samuel E. Dagogo-Jack · 2025 · Diabetes
64. Cardiovascular disease leads to a new algorithm for diabetes treatment
    Valentina Rodriguez, Matthew C. Weiss, HOWARD S. WEINTRAUB, Ira J. Goldberg, Arthur Z. Schwartzbard · 2017 · Journal of clinical lipidology
65. Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: A review
    Sofia Antoniou, Katerina Κ. Naka, Marios Papadakis, Aris Bechlioulis, Agathocles A. Tsatsoulis, Lampros K. Michalis, Stelios K. Tigas · 2021 · World Journal of Diabetes
66. Management of Hyperglycemia in Older Adults with Type 2 Diabetes
    Gunjan Yogendra Gandhi, Arshag D. Mooradian · 2021 · Drugs & Aging
67. Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease
    Zhewen Ren, Anke Wesselius, Coen D.A. Stehouwer, Martijn C.G.J. Brouwers · 2023 · Endocrinology and Metabolism Clinics of North America
68. Association between the insulin resistance and all-cause mortality in patients with moderate and severe aortic stenosis: a retrospective cohort study
    Rihua Huang, Xinghao Xu, Chaoguang Xu, Shaozhao Zhang, Zhenyu Xiong, Menghui Liu, Yiquan Huang, Han Wen, Yue Guo, Xinxue Liao et al. · 2023 · Cardiovascular Diabetology
69. Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes
    Hua Qu, Yi Zheng, Yuren Wang, Rui Zhang, Xiong Zhong Ruan, Gangyi Yang, Zhenqi Liu, Hongting Zheng · 2017 · Scientific Reports
70. Impact of Bone Fracture on Ischemic Stroke Recovery
    Meng Wei, Haiyian Lyu, Kang Huo, Hua Su · 2018 · International Journal of Molecular Sciences
71. SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
    Elamin Abdelgadir, Fouzia Rashid, Alaaeldin M. Bashier, Razan Ali · 2018 · Journal of Clinical Medicine Research
72. Personalized Management of Type 2 Diabetes
    Patricia R. Peter, Beatrice C. Lupsa · 2019 · Current Diabetes Reports
73. Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus
    Bernd M. Balletshofer, Wulf D. Ito, Holger Lawall, Nasser M. Malyar, Yves Oberländer, Peter Reimer, Kilian Rittig, Markus Zähringer · 2019 · Experimental and Clinical Endocrinology & Diabetes
74. Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies
    Theocharis Koufakis, Maria Grammatiki, Kalliopi Kotsa · 2020 · Maturitas
75. Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
    Brian Finan, Sebastian Demian Parlee, Bin S. Yang · 2020 · Molecular Metabolism
76. The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study
    Won Jun Kim, Jung Hyun Noh, Kyungdo Han, Cheol‐Young Park · 2021 · Journal of Alzheimer s Disease
77. Sudden cardiac death in patients with myocardial infarction: 1.5 primary prevention
    Yuntao Feng, Xiang‐Fei Feng · 2021 · Reviews in Cardiovascular Medicine
78. Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study
    Chin-Hsiao Tseng · 2022 · International Journal of COPD
79. Virtual screening of novel compounds as potential ERα inhibitors
    Jakkanaboina TilakVijay, Kandimalla Vivek Babu, Uma Addepally · 2019 · Bioinformation
80. Diabetes and ischaemic stroke: a deadly association
    Gian Paolo Fadini, Francesco Cosentino · 2018 · European Heart Journal
81. Diabetes Drugs and Cardiovascular Safety
    Ji Cheol Bae · 2016 · Endocrinology and Metabolism
82. GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis
    Kayla A. Riggs, Parag H. Joshi, Amit Khera, James D. Otvos, Philip Greenland, Colby R. Ayers, Anand K. Rohatgi · 2022 · American Journal of Preventive Cardiology
83. Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?
    David M. Williams, Michael Atkinson, Marc Evans · 2023 · Stroke
84. Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials
    Minji Sohn, Juan P. Frías, Soo Kyung Lim · 2023 · Diabetes Obesity and Metabolism
85. Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3‐year prospective cohort study
    Ming‐Ling Chang, Jennifer Tai, Jur‐Shan Cheng, Wei‐Ting Chen, Sien‐Sing Yang, Cheng‐Hsun Chiu, Rong‐Nan Chien · 2024 · Diabetes Obesity and Metabolism
86. Response to retention hypothesis as a source of targets for arterial wall-directed therapies to prevent atherosclerosis: A critical review
    Hirushi Kumarapperuma, Zheng-Jie Chia, Sanchia Marie Malapitan, Thomas N. Wight, Peter J. Little, Danielle Kamato · 2024 · Atherosclerosis
87. Role of anti-diabetic medications in the management of MASLD
    Scott D. Isaacs, Fiona V Farrelly, Paul Brennan · 2025 · Frontline Gastroenterology
88. Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk
    Catherine M. Viscoli, David M. Kent, ROBIN A. CONWIT, Jennifer L. Dearborn, Karen L. Furie, Mark Gorman, Peter Guarino, Silvio E. Inzucchi, Amber Stuart, Lawrence H. Young et al. · 2018 · Stroke
89. High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone
    Daejin Kim, Byul‐Nim Ahn, Yeong Seok Kim, Dae Young Hur, Jae Wook Yang, Ga Bin Park, Jung Eun Jang, Eun Ju Lee, Min Jeong Kwon, Tae Nyun Kim et al. · 2019 · Journal of Diabetes Research
90. The efficacy of pioglitazone for renal protection in diabetic kidney disease
    Chao-Chung Ho, Yi‐Sun Yang, Chien‐Ning Huang, Shih‐Chang Lo, Yu‐Hsun Wang, Edy Kornelius · 2022 · PLoS ONE
91. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial
    Abdulla A. Damluji, Erin R. Cohen, Mauro M. Moscucci, Robert J. Myerburg, Mauricio G. Cohen, Maria M. Brooks, Michael W. Rich, Daniel E. Forman · 2017 · International Journal of Cardiology
92. Evidence-Based Cardiovascular Risk Management in Diabetes
    Arshag D. Mooradian · 2019 · American Journal of Cardiovascular Drugs
93. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis
    Guillaume Grenet, Shams Ribault, Giao Bao Nguyen, Faustine Glais, Augustin Metge, Thomas Linet, Behrouz Kassaï, Catherine Cornu, Théodora Bejan‐Angoulvant, Sylvie Erpeldinger et al. · 2019 · PLoS ONE
94. Do triglyceride-lowering drugs decrease risk of cardiovascular disease?
    Maki, Kevin C., Dicklin, Mary R. · 2017 · Current Opinion in Lipidology
95. Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes
    Huili Zhu, Bin Yang, Longyan Lu, Yufeng Li, Rubo Sui, Kewei Liu, Suling Tan, Lihua Wang, Jianmin Qiu, Jianbin Zhong et al. · 2025 · JAMA Internal Medicine
96. Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
    Muhammad Imtiaz Ahmad, Michael David Shapiro · 2021 · Current Atherosclerosis Reports
97. Bladder cancer with pioglitazone: A case–control study
    Bhanu Malhotra, Priya Hiteshi, Persis Khalkho, Ritu Malik, Sanjay Kumar Bhadada, Anil Kumar Bhansali, Nusrat Shafiq, Sameer Malhotra, Narendra Kumar, Rajesh Rajput et al. · 2022 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
98. Efficacy and safety of Gegen Qinlian decoction in the treatment of type II diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials
    YiMei Tan, ShuangHua Liu, MengHe Huang, Hui Cheng, Binbin Xu, HongSheng Luo, QiZhi Tang · 2024 · Frontiers in Endocrinology
99. Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Fernando Bril, Gabriela Alicia Berg, Magalí Barchuk, Juan Patricio Nogueira · 2025 · Journal of Lipid and Atherosclerosis
100. Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old?
     Zachary T. Bloomgarden, DANIEL F. EINHORN, Yehuda Handelsman · 2017 · Diabetes Care